OMICS International

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

 

Recommended Conferences for Sports

Sports


<b> Cancer Bioengineering</b><br><br>

As per available reports about 57 <a href="<http://www.omicsonline.org/scientific-journals.php"> relevant journals </a>, 21<a href=" <http://www.omicsgroup.com/"> Conferences </a> 705 workshops are presently dedicated exclusively to cancer biology about 2455 articles are being published on cancer biology<br/><br/>

Cancer is a disease of misregulated genes, proteins, metabolites, cells, and biophysical forces.  Early-stage cancers are difficult to diagnose and characterize, and late-stage cancers are invariably hard to treat.  Clinically, cancer is an enormous burden on human health and society.  The challenges span multiple spatiotemporal scales and will require engineering approaches to solve. Multi-pronged effort aimed at cancer biology, cancer imaging, and cancer therapy.  Tissue foci include cancers of the breast, brain, pancreas, lung, and kidney. <br/><br/>
 

<a href="<http://www.conferenceseries.com/"> OMICS International </a>Organizes 1000+ <a href="<http://www.conferenceseries.com/"> Global Events </a> Every Year across USA, Europe & Asia with support from 1000 more <a href="<http://www.omicsonline.org/international-societies-world-fedarations-scientific-associations.php "> scientific societies </a> and Publishes 700+ <a href="<http://www.omicsonline.org/open-access-journals-list.php/"> Open access journals </a> which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The <a href="<http://www.conferenceseries.com/"> conference series </a> website will provide you list and details about the conference organize worldwide. <br/><br/>

<b>Scope and Importance: </b><br><br>

The goals of bioengineering strategies for targeted cancer therapies are (1) to deliver a high dose of an anticancer drug directly to a cancer tumor, (2) to enhance drug uptake by malignant cells, and (3) to minimize drug uptake by nonmalignant cells. Effective cancer-targeting therapies will require both passive- and active-targeting strategies and a thorough understanding of physiologic barriers to targeted drug delivery. Designing a targeted therapy includes the selection and optimization of a nanoparticle delivery vehicle for passive accumulation in tumors, a targeting moiety for active receptor-mediated uptake, and stimuli-responsive polymers for control of drug release. The future direction of cancer targeting is a combinatorial approach, in which targeting therapies are designed to use multiple-targeting strategies. The combinatorial approach will enable combination therapy for delivery of multiple drugs and dual ligand targeting to improve targeting specificity. Targeted cancer treatments in development and the new combinatorial approaches show promise for improving targeted anticancer drug delivery and improving treatment outcomes.<br/><br/>
 

<b>Market Analysis: </b><br><br>

Cancer is a generic term for a large group of diseases that can affect any part of the body. Other terms used are malignant tumors and neoplasms. Metastases are the major cause of death from cancer. Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012.

About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world. Breast cancer, the most common tumour in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years. Lung cancer is one of the most aggressive tumors and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years. Colorectal cancer (of the colon and rectum), the most common malignant tumour if we group men and women together, presents an average survival rate of 50-55% five years after diagnosis, meaning that half the patients survive this form of cancer. Prostate cancer, today the most common tumour in men, has an increasingly favorable prognosis, with a global survival rate of 76%, which is higher in young adults. Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.<br/><br/>

 

<b>:Conferences </b>:<br/><br/>

 

·         <a href=" http://cancer.global-summit.com/america/"> 6th World Congress on

Cancer Therapy, USA</a><br/>

·         <a href=" http://cancer.global-summit.com/america/"> 7th  Global Summit on

Cancer Therapy, Dubai, UAE</a><br/>

·         <a href=" http://cancer.global-summit.com/europe/"> 8th Euro Global Summit on

Cancer Therapy, Valencia, Spain</a><br/>

·         <a href=" http://cancer.global-summit.com/india/"> 9th Indo Global Summit on Cancer Therapy, Hyderabad, India</a><br/>

·         <a href=" http://cancer.global-summit.com/asia-pacific/"> 11th Asia-Pacific Oncologists Annual Meeting</a><br/>

·         <a href=" http://integrativebiology.conferenceseries.com/"> Integrative Biology-2016, Berlin, Germany </a><br/>

·         <a href=" http://syntheticbiology.conferenceseries.com/"> Synthetic Biology Conference , USA</a><br/>

<b> Relevant Organization and Associations </b>:<br/><br/>

European Society for Medical Oncology</br>

European Society of Gynaecological Oncology</br>

EuroPharm Forum</br>

Friends of Cancer Research) </br>

American Cancer Society</br>

National Cancer Institute</br>

German Cancer Aid</br>

Cancer Council Australia</br>

Edinburgh Cancer Research Centre</br>

World Cancer Research Fund, UK</br> and many more

<b>:Company list<b>: </br></br>

Roche</br>

Novartis</br>

Celgene</br>

Bristol-Myers Squibb </br>

Lilly </br>

Takeda </br>

Merck & Co. </br>

AstraZeneca </br>

Pfizer </br>

Pharmacyclics </br>

This page will be updated regularly.

This page was last updated on 08th Sep, 2015

Conferenceseries Destinations

Contact Us

Medical Conferences
Jessie Grace
jessie.grace@conferenceseries.com
1-702-508-5200 Ext:8031, 8041

Pharmaceutical Conferences
Badoni Victor
badoni.victor@conferenceseries.com
1-702-508-5200 Ext:8045, 8047

Immunology & Microbiology Conferences
Walker Smith
walker.smith@conferenceseries.com
1-702-508-5200 Ext:8031

Cancer Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Nursing and Healthcare Conferences
Jennifer Leny
jennifer.leny@conferenceseries.com
1-702-508-5200 Ext:8044

Diabetes Conferences
Stanley knight
stanley.knight@conferenceseries.com
1-702-508-5200 Ext:8040

Neuroscience Conferences
Sandeep Kumar
sandeep@conferenceseries.com
1-702-508-5200 Ext:8034

Dental Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Clinical and Biochemistry Conferences
Rohit Casper
rohit.casper@conferenceseries.com
1-702-508-5200 Ext:8033

Biotechnology Conferences
Ravi Vittal
ravi.vittal@conferenceseries.com
1-702-508-5200 Ext:8031, 8037

Material Science Conferences
Lucy Grey
lucygrey@conferenceseries.com
1-702-508-5200 Ext:8035

Genetics & Mol Biology Conferences
Stephen Bruce
stephen.bruce@conferenceseries.com
1-702-508-5200 Ext:8038

Engineering Conferences
Dolly A
dolly@conferenceseries.com
+1-702-508-5200 Ext:8051

Program Enquiries
Symposia/Workshops
Sponsorships
Media Partners | Advertising